Related Experiment Video
Updated: May 20, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
The management of small-cell carcinomas of the gynecologic tract
Joshua G Cohen1, John K Chan, Daniel S Kapp
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Women's Cancer Research Institute, Los Angeles, California, USA.
Purpose Of Review:
Small-cell carcinomas of the gynecologic tract are aggressive malignancies that can be misdiagnosed or inappropriately managed. This review provides a summary of current literature that will help the clinician to correctly diagnose and treat patients with small-cell carcinomas of the cervix, ovary, uterus, vagina, and vulva.
Recent Findings:
Small-cell carcinomas of gynecologic sites are rare and carry a poor prognosis. Stage is an important prognostic factor in small-cell carcinoma of the cervix, uterus, and ovary. Early stage disease has varied treatment approaches based on the site of malignancy, but systemic chemotherapy with or without radiation plays a role in the adjuvant setting to mitigate the risk of recurrence. Advanced stage patients require treatment with chemotherapy and possibly radiation, usually in a manner analogous to small-cell lung cancer. The preferred chemotherapy regimen contains a platinum agent and etoposide. For small-cell ovarian carcinomas, it is important to differentiate those of the hypercalcemic type from those of the pulmonary type. The small-cell carcinomas of the vagina and vulva need to be distinguished from Merkel cell cancers.
Summary:
The majority of small-cell tumors of the gynecologic tract will require systemic chemotherapy with a platinum agent and etoposide, both in the setting of early and advanced stage disease. Prospective trials with new chemotherapy or targeted agents are needed to improve the treatment of this aggressive cancer.
Insights
Small-cell gynecologic cancers are aggressive and rare. Treatment typically involves platinum and etoposide chemotherapy, with stage being a key prognostic factor for cervical, uterine, and ovarian cancers.
Area of Science:
- Gynecologic Oncology
- Pathology
- Medical Oncology
Background:
- Small-cell carcinomas of the gynecologic tract are rare, aggressive malignancies.
- These tumors are prone to misdiagnosis and suboptimal management.
- Accurate diagnosis and treatment are crucial for improving patient outcomes.
Purpose of the Study:
- To review current literature on small-cell carcinomas of the cervix, ovary, uterus, vagina, and vulva.
- To guide clinicians in the correct diagnosis and management of these rare gynecologic cancers.
- To summarize prognostic factors and treatment strategies.
Main Methods:
- Literature review of current research on gynecologic small-cell carcinomas.
- Analysis of diagnostic criteria and prognostic indicators.
- Evaluation of treatment approaches, including chemotherapy and radiation.
Main Results:
- Small-cell gynecologic cancers are rare with a poor prognosis.
- Tumor stage is a significant prognostic factor for cervical, uterine, and ovarian small-cell carcinomas.
- Systemic chemotherapy, often with a platinum agent and etoposide, is the mainstay treatment for both early and advanced stages.
- Distinguishing ovarian small-cell carcinoma subtypes and differentiating vaginal/vulvar small-cell cancers from Merkel cell cancers are critical.
Conclusions:
- Platinum and etoposide-based chemotherapy is the standard treatment for most small-cell gynecologic tumors.
- Further prospective trials investigating novel chemotherapy and targeted agents are necessary to enhance treatment efficacy.
- Early diagnosis and appropriate management are vital for improving outcomes in patients with these aggressive malignancies.
